Cantor Fitzgerald raised the firm’s price target on CyberArk (CYBR) to $415 from $335 and keeps an Overweight rating on the shares. The firm is ...

In a report released today, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Prenetics Group (PRE – Research Report), with a price ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald from ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Onto Innovation (NYSE:ONTO) with a ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Nova (NasdaqGS:NVMI) with a Overweight ...

Analysts at Cantor Fitzgerald initiated coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) in a note issued to investors on Friday, MarketBeat.com reports. The brokerage ...

Cantor Fitzgerald analyst Deepak Mathivanan downgraded Sabre (SABR) to Neutral from Overweight with a price target of $4, down from $5, after assuming coverage of the name. Cantor expects fiscal ...

Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat ...

Cantor Fitzgerald raised its price target for the company Archer Aviation (ACHR, Financial) on Wednesday to $13.00 from $10.00, which pushed Archer stock soared 8% on Wednesday. This helped ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.56% of ...

On Tuesday, Cantor Fitzgerald initiated coverage on Esperion (NASDAQ:ESPR) Therapeutics, a biopharmaceutical company, with an Overweight rating and a price target of $8.00. The firm pointed out ...